Phase 2 Liver Cancer Trial, Recruiting NCT06888063 Sponsor: Erasmus Medical Center Condition: Liver Cancer
Back to Liver Cancer

Phase 2 Liver Cancer Trial, Recruiting

NCT06888063
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You are generally in good health and able to carry out daily activities with little or no limitation (confirm with trial site)
  • Imaging scans show a liver cancer (specifically intrahepatic cholangiocarcinoma) that can be surgically removed — a tissue biopsy is not required before surgery
  • You are healthy enough to have open abdominal surgery
  • Based on a specific type of CT scan, it is possible for surgeons to place a small tube (catheter) into an artery near your liver to deliver chemotherapy directly (confirm with trial site)
  • Your blood counts, liver function, and kidney function are within acceptable levels, tested within the last 30 days
  • You have enough healthy white blood cells, infection-fighting cells (neutrophils), and platelets in your blood
  • Your kidneys are filtering blood at an acceptable rate
  • Your haemoglobin (the part of blood that carries oxygen) is at an acceptable level
  • Your bilirubin level (a measure of liver function) is not too high
  • You are willing and able to give written consent to take part in the trial

Who may not be able to join:

  • The cancer has spread to areas outside the liver at the time of first diagnosis (though patients with very small, uncharacterised lesions of 1 cm or less, or nearby lymph node involvement, may still be eligible — confirm with trial site)
  • You have had another type of cancer, unless it was a common skin cancer, or a previous cancer that was fully treated at least 3 years ago with no signs of return, or one where life expectancy is greater than 5 years
  • You have a known inherited condition that affects how your body breaks down certain chemotherapy drugs (called DPYD deficiency — homozygous type)
  • You have previously had radiation therapy, tumour burning/freezing (ablation), or surgery to remove part of your liver for this type of cancer
  • You have signs of high blood pressure in the liver's blood supply system, such as fluid build-up in the abdomen, swollen veins in the food pipe or stomach, or a blood clot in the main liver vein (some fluid after surgery may be acceptable — confirm with trial site)
  • There is a blood clot in the portal vein of the part of the liver that would remain after surgery
  • You are pregnant or currently breastfeeding
  • You have a significant mental health condition that, in the doctor's judgement, would prevent you from giving informed consent or following the treatment plan
  • You have other serious health conditions that could put you at risk or prevent you from completing the study
  • You have received a transplanted organ and need medication to prevent rejection
  • You have a serious infection that is not under control or is currently being treated
  • You are already taking part in another interventional clinical trial for this type of liver cancer that measures survival as an outcome
  • You are already taking part in another clinical study involving an investigational medical treatment
  • There are personal, psychological, family, social, or location-related circumstances that might make it difficult to follow the study plan and attend follow-up appointments (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bas Groot Koerkamp, MD, PhD, Erasmus Medical Center

Phone: +31(0)107031810

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Erasmus Medical Center
Registry
ClinicalTrials.gov
Start date
20 November 2024
Est. completion
1 September 2026

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Two-year hepatic recurrence free survival (hRFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov